Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Quadrivalent Influenza Vaccine in Children 6-35 Months
NCT05642078Phase 3Completed
- Sponsor
- Zhifei Biological
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of influenza virus vaccine, quadrivalent, split virion in influenza (3 arms), sponsored by Zhifei Biological. Primary endpoints: Hemagglutination Inhibition (HAI) Antibody Titers and Incidence of Adverse Events at 6 months. Started Feb 2023; status: completed.
02
Drugs
influenza virus vaccine, quadrivalent, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05642078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05642078.